Although several similarities exist between gilteritinib and crenolanib (eg, effective inhibition of FLT3-D835Y and high selectivity for FLT3 compared with c-KIT), crenolanib treatment showed limited efficacy at the maximum tolerated dose in a xenograft mouse model in which MV4–11-luc cells were inoculated by intravenous injection, resulting in a significant survival benefit without a complete reduction in tumor cells [24]. The gene discussed is KIT; the disease is neoplasm.